^
    Back
    Association details:
    Biomarker:IL6 elevation
    Cancer:Renal Cell Carcinoma
    Drug:pazopanib (Multi-tyrosine kinase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Cancers (Basel)
    Title:

    Circulating Levels of the Interferon-γ-Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy

    Published date:
    06/07/2021
    Excerpt:
    In conclusion, high plasma HGF, CXCL11, CXCL10 and IL-6 levels are associated with worse outcome in mRCC patients treated with sunitinib or pazopanib.
    DOI:
    10.3390/cancers13112849